High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.

ABSTRACT:

Background

Cemiplimab (Libtayo^®), a human monoclonal immunoglobulin G4 antibody to the programmed cell death-1 receptor, is approved for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC), who are not candidates for curative surgery or curative radiation, using an every-3-weeks (Q3W) dosing interval. Pharmacokinetic modeling indicated that C_trough of extended intravenous dosing of 600 mg every 4 weeks (Q4W) would be comparable to the approved intravenous dosage of 350 mg Q3W. We examined the efficacy, pharmacokinetics, and safety of cemiplimab dosed Q4W.

Methods

In this open-label, phase II trial (ClinicalTrials.gov identifier NCT02760498), the cohort of patients ≥18 years old with advanced CSCC received cemiplimab 600 mg i

SUBMITTER: Rischin D 

PROVIDER: S-EPMC10936461 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature